|
Market Closed -
NSE India S.E.
09:05:08 08/09/26 pm AEST
|
5-day change | 1st Jan Change | ||
| 2,474.50 INR | +0.92% |
|
-0.22% | +21.59% |
| 07/09 | Acucort wins trademark protection for Zeqmelit in Ukraine | FW |
| 20/08 | Glenmark Pharmaceuticals Limited Receives U.S. FDA Approval For Fluticasone Propionate Nasal Spray 0.05 Mg (50 Mcg)/Spray | CI |
| Market Cap | 698B 7.37B 6.33B 5.96B 5.44B 10.15B 10.2B 70.59B 27.31B 357B 27.66B 27.06B 1,136B | P/E 2027 * |
30.1x | P/E 2028 * | 25x |
|---|---|---|---|---|---|
| Enterprise Value | 662B 6.98B 6B 5.65B 5.15B 9.62B 9.67B 66.91B 25.89B 338B 26.21B 25.64B 1,076B | EV / Sales 2027 * |
3.94x | EV / Sales 2028 * | 3.48x |
| Free-Float |
51.04% | Yield 2027 * |
0.15% | Yield 2028 * | 0.16% |
| Markets | Quality | ||
|---|---|---|---|
NSE India S.E.
| GLENMARK | Delayed | |
Bombay S.E.
| GLENMARK | Delayed |
Last Transcript : Glenmark Pharmaceuticals Limited
| 1 day | +0.92% | ||
| 1 week | -0.22% | ||
| Current month | -0.22% | ||
| 1 month | +8.57% | ||
| 3 months | +14.23% | ||
| 6 months | +16.48% | ||
| Current year | +21.59% |
| 1 week | 2,420 |  | 2,492 |
| 1 month | 2,222.5 | | 2,537.6 |
| Current year | 1,842 | | 2,537.6 |
| 1 year | 1,792.6 | | 2,537.6 |
| 3 years | 722.1 | | 2,537.6 |
| 5 years | 348.5 | | 2,537.6 |
| 10 years | 161.65 | | 2,537.6 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 56 | 01/01/2000 | |
Anurag Mantri
DFI | Director of Finance/CFO | 54 | 27/05/2025 |
Indrajit Bose
PSD | President | - | 15/09/2023 |
| Director | Title | Age | Since |
|---|---|---|---|
Cherylann Pinto
BRD | Director/Board Member | 58 | - |
| Chairman | 56 | 12/05/2011 | |
| Director/Board Member | 86 | 14/08/2009 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.92% | -0.22% | +20.60% | +211.71% | 7.32B | |
| -0.48% | -4.98% | +18.34% | +66.44% | 48.08B | |
| +0.60% | -3.67% | +43.01% | +112.23% | 39.95B | |
| -0.79% | -1.79% | -10.91% | +10.78% | 11.92B | |
| -0.99% | -1.36% | +12.99% | +80.96% | 12.2B | |
| -0.38% | -0.76% | +24.29% | +137.27% | 9.22B | |
| -1.02% | -4.04% | +21.19% | +33.90% | 7.41B | |
| +0.25% | -1.06% | +39.66% | -12.93% | 7.37B | |
| -0.77% | -2.60% | -46.73% | +21.08% | 5.17B | |
| +1.87% | -0.63% | +36.92% | +103.14% | 4.64B | |
| Average | -0.08% | -1.93% | +15.94% | +76.46% | 15.33B | |
| Weighted average by Cap. | -0.12% | -3.01% | +22.07% | +80.59% |
| 2027 * | 2028 * | |
|---|---|---|
| Net sales | 168B 1.77B 1.52B 1.43B 1.31B 2.44B 2.45B 16.98B 6.57B 85.83B 6.65B 6.51B 273B | 187B 1.97B 1.7B 1.6B 1.46B 2.72B 2.73B 18.92B 7.32B 95.64B 7.41B 7.25B 304B |
| Net income | 23.11B 244M 210M 197M 180M 336M 338M 2.34B 904M 11.81B 915M 895M 37.59B | 27.71B 292M 251M 236M 216M 403M 405M 2.8B 1.08B 14.16B 1.1B 1.07B 45.07B |
| Net Debt | -36.49B -385M -331M -311M -284M -530M -533M -3.69B -1.43B -18.65B -1.45B -1.41B -59.35B | -48B -506M -435M -410M -374M -698M -701M -4.85B -1.88B -24.54B -1.9B -1.86B -78.08B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 08/09/26 | INR 2,474.50 | +0.92% | 447,432 |
| 07/09/26 | INR 2,451.90 | +0.60% | 267,568 |
| 04/09/26 | INR 2,437.20 | -0.89% | 412,728 |
| 03/09/26 | INR 2,459.00 | -0.04% | 481,343 |
| 02/09/26 | INR 2,460.00 | -0.42% | 516,029 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- GLENMARK Stock
Select your edition
All financial news and data tailored to specific country editions
